Clinical trials: Placebo Drug Interaction
Heart Failure
A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure
This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.
- Trial name
- NCT01125514
- Testing
- Aliskiren 150 mg, Furosemide 60 mg, Aliskiren 300 mg
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Gout
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
- Trial name
- NCT01129648
- Testing
- Allopurinol, BCX4208
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- BioCryst Pharmaceuticals
Alcoholism
Alcohol Interaction Study
The purpose of this study is understand the effects of GSK114814 and alcohol in healthy volunteers when taken together.
- Trial name
- NCT01181908
- Testing
- single dose
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Subjects
Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949
This is a prospective, single-center, double-blind, randomized, placebo-controlled, ascending single oral dose and food interaction Phase 1 study.
- Trial name
- NCT02099071
- Testing
- ACT-389949 1 mg, ACT-389949 5 mg, ACT-389949 20 mg
- Where
- Netherlands
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Epilepsy
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record.
- Trial name
- NCT02565108
- Testing
- GWP42003-P 20 mg/kg/Day Dose, Clobazam
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Jazz Pharmaceuticals
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on…
- Trial name
- NCT07283263
- Testing
- BMS-985521
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure
A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure
The study will examine midazolam pharmacokinetics following single dose administration of 3 planned dose levels of GGF2 .
- Trial name
- NCT01944683
- Testing
- GGF2, Midazolam
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Acorda Therapeutics
Healthy
GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of multiple increasing oral doses of GLPG0259 compared to placebo.
- Trial name
- NCT00989703
- Testing
- GLPG0259, Methotrexate
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Bacterial Infections
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
A phase 1, randomized, double blind, placebo controlled drug-drug interaction, pharmacokinetics and safety study of cefiderocol in combination with xeruborbactam in healthy adult participants
- Trial name
- NCT06547554
- Testing
- Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Healthy Volunteers
A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects
To evaluate if Brivaracetam (BRV) influences the psychomotor and cognitive impairing effects of Ethanol
- Trial name
- NCT01710670
- Testing
- Brivaracetam, Ethanol
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UCB Pharma SA
Hepatitis C
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.
- Trial name
- NCT00958152
- Testing
- VCH-222, telaprevir
- Where
- New Zealand
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Parkinson's Disease
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
The purpose of this study is to investigate the tolerability, pharmacokinetic profile of BIA 3-202 and its metabolites, and the pharmacokinetic and pharmacodynamic interaction between 4 different single doses of BIA 3-202 (50 mg…
- Trial name
- NCT02763852
- Testing
- BIA 3-202, Madopar® 125
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Volunteer
Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response
The purpose of this study is to evaluate the potential effect of ozanimod on pressor response when co-administered with oral tyramine in healthy adult subjects.
- Trial name
- NCT03694119
- Testing
- Phenelzine, Tyramine, ozanimod
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with omeprazole 80 mg/day compared to…
- Trial name
- NCT01129375
- Testing
- clopidogrel, omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pharmacokinetics of ASP8477, Pharmacodynamics of ASP8477
A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males
This is a 4-part study. Part I assesses the safety and tolerability of single ascending doses of ASP8477 or a placebo under fasted conditions in postmenopausal subjects.
- Trial name
- NCT02220777
- Testing
- ASP8477, omeprazole
- Where
- 2 sites in Belgium, France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults.
- Trial name
- NCT05393271
- Testing
- VH4011499, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169453
- Testing
- BIA 9-1067, Sinemet® CR 100/25
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypercholesterolemia
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
This study will assess the safety, atorvastatin pharmacokinetics, and LDL-C lowering efficacy of ETC-1002 versus placebo in hypercholesterolemic subjects on background therapy of atorvastatin 10 mg.
- Trial name
- NCT01779453
- Testing
- ETC-1002, Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Esperion Therapeutics, Inc.
Erectile Dysfunction
A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol
The purpose of this study is primarily to evaluate the effects of simultaneous administration of Tunodafil Hydrochloride Tablets with alcohol on blood pressure, pulse rate and pharmacokinetics in healthy Chinese male participants.
- Trial name
- NCT05976503
- Testing
- Tunodafil Hydrochloride Tablets, Alcohol
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Yangtze River Pharmaceutical Group Co., Ltd.